Lista de obras - Marta Schirripa - Dominio Público Uruguay

12-chemokine signature, a predictor of tumor recurrence in colorectal cancer

scientific article published on 19 March 2020

A polymorphism within the vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab or FOLFIRI/cetuximab

artículo científico publicado en 2017

AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3

artículo científico publicado en 2019

Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.

artículo científico publicado en 2017

Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.

artículo científico publicado en 2017

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.

artículo científico publicado en 2015

Biomarker in Colorectal Cancer.

artículo científico publicado en 2016

Biomarker-driven and molecular targeted therapies for colorectal cancers

scientific article published on 04 July 2017

Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab

artículo científico publicado en 2016

Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer

artículo científico publicado en 2011

Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients.

artículo científico publicado en 2016

Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.

artículo científico publicado en 2015

Colorectal cancer: Overcoming resistance to anti-EGFR therapy - where do we stand?

artículo científico publicado en 2016

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.

artículo científico publicado en 2015

Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer.

artículo científico publicado en 2011

Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.

artículo científico publicado en 2018

EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.

artículo científico publicado en 2013

EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle

artículo científico publicado en 2012

FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).

artículo científico publicado en 2013

FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer

artículo científico publicado en 2013

First-line chemotherapy for mCRC—a review and evidence-based algorithm.

artículo científico

Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.

artículo científico publicado en 2018

Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients

article

Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.

artículo científico publicado en 2017

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.

artículo científico publicado en 2013

Immunotherapy in Gastrointestinal Cancers.

artículo científico publicado en 2017

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials

artículo científico publicado en 2017

Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012.

artículo científico publicado en 2016

NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients

artículo científico publicado en 2018

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

artículo científico publicado en 2011

Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.

artículo científico publicado en 2015

Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.

artículo científico publicado en 2017

Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer

artículo científico publicado en 2017

Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.

artículo científico publicado en 2018

Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients

artículo científico publicado en 2014

Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab

artículo científico publicado en 2013

Relationship between MLH1, PMS2, MSH2, and MSH6 gene specific alterations and tumor mutational burden (TMB) in 1,057 microsatellite instability-high solid tumors

scientific article published on 24 May 2020

Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'

artículo científico publicado en 2013

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

artículo científico publicado en 2011

Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.

artículo científico publicado en 2014

Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.

artículo científico publicado en 2017

TAS-102 for the treatment of metastatic colorectal cancer.

artículo científico publicado en 2015

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.

artículo científico publicado en 2017

Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

artículo científico publicado en 2017

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.

artículo científico publicado en 2018

The role of pharmacogenetics in the new ESMO colorectal cancer guidelines.

artículo científico publicado en 2017

The role of tumor angiogenesis as a therapeutic target in colorectal cancer

artículo científico publicado en 2018

Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer

artículo científico publicado en 2016

Lista de obras de Marta Schirripa

12-chemokine signature, a predictor of tumor recurrence in colorectal cancer

A polymorphism within the vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab or FOLFIRI/cetuximab

AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3

Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.

Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.

Biomarker in Colorectal Cancer.

Biomarker-driven and molecular targeted therapies for colorectal cancers

Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab

Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer

Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients.

Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.

Colorectal cancer: Overcoming resistance to anti-EGFR therapy - where do we stand?

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.

Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer.

Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.

EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.

EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle

FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).

FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer

First-line chemotherapy for mCRC—a review and evidence-based algorithm.

Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.

Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients

Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.

Immunotherapy in Gastrointestinal Cancers.

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials

Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012.

NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.

Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.

Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer

Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.

Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients

Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab

Relationship between MLH1, PMS2, MSH2, and MSH6 gene specific alterations and tumor mutational burden (TMB) in 1,057 microsatellite instability-high solid tumors

Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.

Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.

TAS-102 for the treatment of metastatic colorectal cancer.

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.

Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.

The role of pharmacogenetics in the new ESMO colorectal cancer guidelines.

The role of tumor angiogenesis as a therapeutic target in colorectal cancer

Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer